Mettetevi in contatto con noi oggi stesso!
Volete saperne di più sui nostri servizi? Compilate il modulo sottostante e vi contatteremo al più presto per fornirvi tutte le informazioni necessarie e rispondere alle vostre domande.
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr.
Fonte
Tipo di fonte
Diagnosi
Settore medico
Anno di applicazione
Terapia
Paese
Età del destinatario
1801
Apheresis
Allogeneic
Hodgkin Disease
Hematology
2024
Standard Therapy
Poland
28
1802
Apheresis
Allogeneic
Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Poland
23
1803
Apheresis
Allogeneic
Hypoplastic Myelodysplastic Syndrome/Acute Myelogenous Leukemia
Hematology
2024
Standard Therapy
Poland
71
1804
Apheresis
Allogeneic
Infant Acute Lymphoblastic Leukemia
Hematology
2024
Standard Therapy
Poland
41
1805
Apheresis
Allogeneic
Kutanes T-Zell-Lymphom, Mycosis Fungoides
Hematology
2024
Standard Therapy
Poland
72
1806
Apheresis
Autologous
Mantle Cell Lymphoma
Hematology
2024
Standard Therapy
Germany
51
1807
Apheresis
Autologous
Mantle Cell Lymphoma
Hematology
2024
Standard Therapy
Germany
64
1808
Apheresis
Autologous
Mantle Cell Lymphoma
Hematology
2024
Standard Therapy
Germany
66
1809
Apheresis
Autologous
Mantle Cell Lymphoma
Hematology
2024
Standard Therapy
Germany
52
1810
Apheresis
Autologous
Morbus Hodgkin
Hematology
2024
Standard Therapy
Germany
63
1811
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Poland
43
1812
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
52
1813
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
54
1814
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
60
1815
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
61
1816
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
62
1817
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
62
1818
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
62
1819
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
62
1820
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
63
1821
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
64
1822
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
65
1823
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
65
1824
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
66
1825
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
66
1826
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
67
1827
Apheresis
Allogeneic
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
68
1828
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
69
1829
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
70
1830
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
71
1831
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
72
1832
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
66
1833
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
62
1834
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
58
1835
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
61
1836
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
61
1837
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
62
1838
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
70
1839
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
74
1840
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
58
1841
Apheresis
Autologous
Multiple Myeloma
Hematology
2024
Standard Therapy
Germany
63
1842
Apheresis
Allogeneic
Myelodysplastic
Hematology
2024
Standard Therapy
Poland
68
1843
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
20
1844
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
22
1845
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
54
1846
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Germany
58
1847
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
60
1848
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
62
1849
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
65
1850
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
67
1851
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
67
1852
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
67
1853
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Germany
69
1854
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Germany
69
1855
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
70
1856
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Germany
71
1857
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
73
1858
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Germany
60
1859
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
53
1860
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
69
1861
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
59
1862
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
60
1863
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
49
1864
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
52
1865
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
63
1866
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
66
1867
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
58
1868
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
67
1869
Apheresis
Allogeneic
Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
65
1870
Apheresis
Allogeneic
Myelodysplastic Syndrome + Myeloma
Hematology
2024
Standard Therapy
Germany
67
1871
Apheresis
Allogeneic
Myelofibrosis
Hematology
2024
Standard Therapy
Poland
40
1872
Apheresis
Allogeneic
Myelofibrosis
Hematology
2024
Standard Therapy
Poland
58
1873
Apheresis
Allogeneic
Myelofibrosis Myeloid Metaplasia
Hematology
2024
Standard Therapy
Poland
60
1874
Apheresis
Allogeneic
Myelofibrosis Post. Polycythemia Vera
Hematology
2024
Standard Therapy
Poland
66
1875
Apheresis
Allogeneic
Myelofibrosis With Myeloid Metaplasia
Hematology
2024
Standard Therapy
Poland
67
1876
Apheresis
Allogeneic
Myeloma
Hematology
2024
Standard Therapy
Germany
65
1877
Apheresis
Allogeneic
Myeloproliferative Neoplasms
Hematology
2024
Standard Therapy
Poland
74
1878
Apheresis
Allogeneic
Myeloproliferative Neoplasms/Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
68
1879
Apheresis
Autologous
Non-Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Germany
23
1880
Apheresis
Autologous
Non-Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Germany
50
1881
Apheresis
Allogeneic
Non-Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Poland
50
1882
Apheresis
Autologous
Non-Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Germany
67
1883
Apheresis
Allogeneic
Non-Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Poland
46
1884
Apheresis
Allogeneic
Non-Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Poland
65
1885
Apheresis
Autologous
Non-Hodgkin Lymphoma
Hematology
2024
Standard Therapy
Germany
66
1886
Apheresis
Autologous
Non-Hodgkin Lymphoma – relapse
Hematology
2024
Standard Therapy
Germany
54
1887
Apheresis
Autologous
Nonseminoma
Hematology
2024
Standard Therapy
Germany
38
1888
Apheresis
Allogeneic
Osteomyelitis
Hematology
2024
Standard Therapy
Poland
65
1889
Apheresis
Allogeneic
Post-Et-Myelofibrosis
Hematology
2024
Standard Therapy
Poland
59
1890
Apheresis
Allogeneic
Post-Pv-Myelofibrosis
Hematology
2024
Standard Therapy
Poland
64
1891
Apheresis
Autologous
Primary Central Nervous System Lymphoma
Hematology
2024
Standard Therapy
Germany
60
1892
Apheresis
Allogeneic
Primary Myelofibrosis
Hematology
2024
Standard Therapy
Poland
52
1893
Apheresis
Allogeneic
Primary Myelofibrosis
Hematology
2024
Standard Therapy
Poland
67
1894
Apheresis
Allogeneic
Primary Myelofibrosis
Hematology
2024
Standard Therapy
Poland
70
1895
Apheresis
Allogeneic
Relapsed B-Cell Acute Lymphoblastic Leukemia
Hematology
2024
Standard Therapy
Poland
12
1896
Apheresis
Allogeneic
Severe Aplastic Anemia
Hematology
2024
Standard Therapy
Poland
15
1897
Apheresis
Allogeneic
Severe Aplastic Anemia
Hematology
2024
Standard Therapy
Poland
10
1898
Apheresis
Allogeneic
Severe Aplastic Anemia
Hematology
2024
Standard Therapy
Poland
60
1899
Apheresis
Allogeneic
Severe Aplastic Anemia Progressed To Myelodysplastic Syndrome
Hematology
2024
Standard Therapy
Poland
21
1900
Apheresis
Autologous
Multiple myeloma
Hematology
2024
Standard Therapy
Germany
63